Weill Medical College of Cornell University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Weill Medical College of Cornell University sits in the top decile of US sponsors by registered trial count (#49 of 15,742 sponsors by registered trial count).

701 total trials 127 currently recruiting 387 completed early-phase tilt top decile by trial count

Weill Medical College of Cornell University: 701 sponsored US clinical trials, 127 recruiting.

Weill Medical College of Cornell University sponsors 701 registered US clinical trials on ClinicalTrials.gov, 127 of them currently recruiting, and 387 completed. 89 of these trials are in Phase 3-4 (later-stage) and 197 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 20 trials.

Top-decile sponsor footprint

Weill Medical College of Cornell University ranks in the top decile of sponsors by registered trial count (#49 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 27/100

387 of 515 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

701 total, page 8 of 15

COMPLETED NA

Pain Screening in Refugee Survivors of Torture

NCT03018782

TERMINATED NA

The Efficacy of a New Mathematical Formula to Predict Continuous Positive Air Pressure With an Oronasal Mask Interface.

NCT02816255

COMPLETED Phase 2

Impact of Duloxetine on Male Fertility

NCT03038867

COMPLETED Phase 2

Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer

NCT02904954

TERMINATED Phase 2

A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers

NCT03115801

COMPLETED Phase 1

Fecal Microbiota Transplantation (FMT) in the Management of Ulcerative Colitis (UC)

NCT02516384

TERMINATED NA

Randomized Trial of Image -Guided Stereotactic Radiation Therapy (IG-SRT) in Prostate Cancer

NCT02911922

COMPLETED NA

Can Cognitive Training Decrease Reactive Aggression?

NCT03623477

TERMINATED Phase 4

Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS

NCT02446886

COMPLETED

Biology of the Oral Epithelium of E-Cigarette Smokers

NCT03028558

COMPLETED

Mechanisms of Ischemic Stroke in Cancer Patients

NCT02604667

COMPLETED NA

Improving Medication Adherence in the Alabama Black Belt

NCT02274844

COMPLETED Phase 1

Evaluation of the Effect of Dried Cranberry Powder in Women With Dry OAB

NCT03017170

COMPLETED NA

Strides for Life I: Increasing Physical Activity in Stage 1 Lung Cancer Patients

NCT02755883

COMPLETED NA

Peer Mentored Approaches For Men And Women With Coronary Artery Disease ("4Steps")

NCT03020316

COMPLETED Phase 2

A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms

NCT03075826

COMPLETED NA

A ProspectiveTrial Comparing THUNDERBEAT to the Ligasure Energy Device During Laparoscopic Colon Surgery

NCT02628093

COMPLETED Phase 1

Neoadjuvant J591 Treatment for Prostate Cancer

NCT02693860

COMPLETED Phase 4

Prospective, Double Blind, Placebo Control, Bariatric IV Ace

NCT02452320

TERMINATED Phase 3

BiRd vs. Rd as Initial Therapy in Multiple Myeloma

NCT02516696

COMPLETED NA

An 18-Month Psychotherapy of Borderline Personality Disorder

NCT03329677

COMPLETED NA

Safety of Caprylic Triglycerides in ALS: A Pilot Study

NCT02716662

COMPLETED NA

Essential Voice Tremor: A Study of Botulinum Toxin Treatment and Injection Augmentation

NCT02711995

COMPLETED Phase 1

KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma

NCT02471911

COMPLETED NA

The Effect of White Noise In High Noise Environment

NCT02647138

COMPLETED

Polymorphisms at Distinct Genetic Loci Affect Response to Anti-CD20 Monoclonal Antibody Therapies

NCT02694913

COMPLETED NA

Pilot Trial of a Social Skills Group Treatment (Secret Agent Society Program)

NCT02574273

TERMINATED NA

Trial of RiaSTAP Versus Cryoprecipitate to Lower Operative Transfusions

NCT02540434

TERMINATED Phase 2

IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia

NCT02508324

TERMINATED Phase 2

LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer

NCT02538471

TERMINATED

Immune Modulators and IVF

NCT02626702

COMPLETED NA

Delayed Cord Clamping in Preterm Neonates

NCT02478684

COMPLETED Phase 1

J591 in Patients With Advanced Prostate Cancer and Unfavorable Circulating Tumor Cell Counts

NCT02552394

TERMINATED NA

Commercial Single Step (Vitrolife -G-TL™) Media Compared With Cornell Media

NCT02527642

TERMINATED Phase 2

Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML

NCT02532010

TERMINATED

Mobile Phone Technology for Chronic Pain Patients- A Feasibility Study

NCT02447107

TERMINATED NA

Temperature Manipulating Gloves for the Treatment of Insomnia

NCT02341287

COMPLETED

Integrative-omics of the Disordered COPD Small Airway Epithelium

NCT02183818

COMPLETED

Reduction of Peanut Reactivity and Immune Modulation With Anti-IgE Therapy

NCT02194530

COMPLETED Phase 2

Study of Clinical Efficacy and Safety of Tosedostat in MDS

NCT02452346

TERMINATED Phase 1

Efficacy of Quetiapine for Pediatric Delirium

NCT02056171

COMPLETED Phase 2

Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR

NCT02497404

COMPLETED

Hormonal Predictors of Oncologic Surgery

NCT02471157

COMPLETED Phase 2

Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy

NCT02353728

TERMINATED NA

Use of Rotational Thromboelastometry (ROTEM) to Characterize Coagulation Abnormalities in Burn Patients

NCT02388776

COMPLETED NA

Case Studies: Promoting Strategy Use in Functional Activities

NCT04363645

COMPLETED NA

Doxycycline for COPD in HIV-Infected Patients

NCT01744093

COMPLETED NA

Depression, Obesity and Inflammatory Markers

NCT02765100

COMPLETED

Identification and Treatment of Thrombotic Microangiopathies in Allogeneic Stem Cell Transplants

NCT02604420

COMPLETED

Aggressive Onset Multiple Sclerosis: A Practical Definition and Study of Its Clinical Course

NCT02301572

← Previous Page 8 of 15 Next →

Phase Distribution

PhaseTrial count
Phase 1 86
Phase 2 111
Phase 3 26
Phase 4 63

What is open in the Weill Medical College of Cornell University pipeline

127 recruiting of 701 indexed (18% open); 387 completed (55%).

Phase mix: 89 late (III/IV) vs 197 early (I/II) (early-phase heavy).

Top condition: Prostate Cancer (20 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Weill Medical College of Cornell University: open-pipeline peers nationwide

Peers matched on 701 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

Weill Medical College of Cornell University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600800 5%10%15%20%25% Total trials Recruiting share Weill Medical College of Cornell UniversityIcahn School of Medicine at Mount SinaiSanofiThe Cleveland ClinicUniversity of MiamiChildren's Hospital of PhiladelphiaUniversity of California, BerkeleyBurke Medical Research InstituteGrand Valley State University
Weill Medical College of Cornell University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Weill Medical College of Cornell University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 701 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this Weill Medical College of Cornell University page

701 registered trials is a research-attention snapshot, not an endorsement of Weill Medical College of Cornell University or any single study.

  • 127 of Weill Medical College of Cornell University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prostate Cancer is the condition Weill Medical College of Cornell University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Weill Medical College of Cornell University pipeline card: 701 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.